213 
So, in summary, I would like to say that we continue committed to 
voluntary compliance with the Guidelines. In that compliance we feel that 
our firms will certainly abide by the safety provisions that are contained 
therein, and we are hopeful that on the basis of these present revisions, 
some accommodation can be made to protect the industrial property rights of 
any of our member firms who may be so engaged or become engaged in the 
future . 
Thank you. 
DR. FREDRICKSON: Thank you, Dr. Adams. Would you remain at the podium 
in case there are — 
Dr. Ahmed. 
DR. AHMED: I am pleased to hear that industry has taken the initiative 
to voluntarily comply with the NIH Guidelines. However, what is the actual 
industry mechanism for monitoring? You said as far as you know there is 
complete compliance. But how can you be assured of that, particularly with 
respect to small companies. What kind of mechanism do you have within your 
industry to implement what you are saying is voluntary compliance? 
Secondly, how can the public, or even the NIH, for that matter, have 
access to that information at this time? 
DR. ADAMS: Well, at the moment the only assurance we have is that we 
have a stated policy, and have to assume that our member firms are in com- 
pliance . 
DR. AHMED: You are assuming that? 
DR. ADAMS: We assume it, and it is very easy for us to make a phone 
call and ask. 
DR. AHMED: That is the only extent of your monitoring, a phone call? 
DR. ADAMS: Yes. We are depending on the integrity of the individual 
companies who have committed themselves to a policy. 
DR. AHMED: Small and big, it doesn't matter what size the company. 
DR. SHAW: He said there were only three companies. 
DR. AHMED: Only three companies are involved? 
DR. ADAMS: Only three companies are involved, yes. 
DR. AHMED: And they are all rather large? 
DR. ADAMS: Yes, they are large companies. 
[ 417 ] 
